Anaphylaxis Treatment Market Forecast Trends - Market Size, Share, Growth Analysis Report (2026-2035)

Anaphylaxis Treatment Market Overview

Anaphylaxis treatment involves prompt administration of epinephrine, followed by supportive care such as antihistamines, corticosteroids, and oxygen therapy to stabilize the patient and prevent recurrence. Rapid response is critical to reduce the risk of complications and fatal outcomes. The market is witnessing growth due to rising allergy prevalence, increased awareness, and improved access to emergency care. The market was valued at USD 2.32 Billion in 2025 and is expected to expand with advancements in auto-injector technology and broader distribution channels. Supportive government initiatives and increasing incidence of anaphylactic reactions further drive market demand across developed and emerging economies.

Anaphylaxis Treatment Market Growth Drivers

Rising Incidence of Anaphylaxis to Enhance Market Growth

The increasing prevalence of anaphylaxis is a significant growth driver of the treatment market. According to Kevin McLendon et al. 2023, the incidence of anaphylaxis in the United States doubled over the past two decades, with approximately 1,500 deaths reported annually. This alarming rise underscores the urgent need for effective emergency treatments and preventive therapies. Consequently, the demand for epinephrine auto-injectors and advanced biologics is projected to drive consistent market expansion.

Anaphylaxis Treatment Market Trends

Key trends in the market include the rise of needle-free innovations and the growing adoption of epicutaneous immunotherapy.

Needle-Free Innovations Driving Growth in the Market

The market is experiencing a notable shift toward innovative, patient-friendly solutions, particularly needle-free drug delivery systems. This trend addresses key concerns around needle phobia and delays in emergency treatment. For instance, in February 2025, ARS Pharmaceuticals advanced this movement by filing for the approval of neffy®, a needle-free epinephrine nasal spray, in Canada and the UK, following its 2024 approval in the U.S. and Europe. As acceptance of non-invasive treatments expands, this trend is expected to significantly boost global market growth.

Epicutaneous Immunotherapy Emerging as a Game-Changer in Pediatric Allergy Management and Boost Anaphylaxis Treatment Market Demand

A notable trend in the market is the development of innovative, non-invasive therapies targeting pediatric food allergies. In February 2025, DBV Technologies announced promising results from a three-year study of the VIASKIN® Peanut patch, showing improved peanut tolerance and sustained safety in toddlers. This advancement in epicutaneous immunotherapy signals strong potential to transform long-term allergy care and is expected to significantly boost market growth.

Anaphylaxis Treatment Market Share

Food Allergies to Lead the Market Share Based on Allergen Type

There are several allergens that can trigger life-threatening anaphylactic reactions, including food, insect stings, medications, and other environmental factors. In the anaphylaxis treatment market, segmentation by allergen type includes food allergies, insect allergies, drug allergies, and others. Among these, food allergies are expected to lead the market due to their rising global prevalence and increasing public health burden. According to the Food Allergy Research and Education (FARE) organization, approximately 33 million people in the United States alone have at least one food allergy. Notably, nearly 11% of U.S. adults, over 27 million individuals report suffering from food allergies. This rising incidence significantly drives the demand for rapid and effective treatment options, positioning food allergies as the dominant segment in the anaphylaxis treatment market.

Anaphylaxis Treatment Market Analysis by Region

The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States remains dominant, bolstered by a robust healthcare infrastructure, strong regulatory support, and ongoing innovation. Notably, in June 2025, the FDA accepted Aquestive Therapeutics’ New Drug Application for Anaphylm, a sublingual epinephrine film for treating anaphylaxis and other type 1 allergic reactions. As a needle‑free, ultra‑portable alternative to traditional autoinjectors, Anaphylm addresses critical issues of compliance, convenience, and patient accessibility. This development underscores the United States’ position at the forefront of anaphylaxis treatment advancements.

Leading Players in the Anaphylaxis Treatment Market

Other key players in the market include AstraZeneca plc, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Merck and Co., Inc., and Glaxosmithkline Plc.

Anaphylaxis Treatment Market Segmentation

Key Questions Answered in the Anaphylaxis Treatment Market Report

• What was the anaphylaxis treatment market value in 2025?
• What is the anaphylaxis treatment market forecast outlook for 2026-2035?
• What are the major factors aiding the anaphylaxis treatment market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Anaphylaxis Treatment market trends?
• Which allergen type is expected to dominate the market segment?
• Which drug class is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which age group is expected to dominate the market segment?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players involved in the anaphylaxis treatment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?